MediWound Analyst Ratings
MediWound Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/21/2023 | 187.29% | HC Wainwright & Co. | $23 → $26 | Maintains | Buy |
| 08/17/2023 | 297.79% | Oppenheimer | $63 → $36 | Maintains | Outperform |
| 08/17/2023 | 154.14% | HC Wainwright & Co. | → $23 | Reiterates | Buy → Buy |
| 05/31/2023 | 596.13% | Oppenheimer | → $63 | Reiterates | Outperform → Outperform |
| 05/31/2023 | 154.14% | HC Wainwright & Co. | → $23 | Reiterates | Buy → Buy |
| 03/17/2023 | 154.14% | HC Wainwright & Co. | → $23 | Reiterates | → Buy |
| 01/04/2023 | 154.14% | HC Wainwright & Co. | $5.5 → $23 | Maintains | Buy |
| 12/30/2022 | 176.24% | Cowen & Co. | $6 → $25 | Maintains | Outperform |
| 12/22/2022 | 176.24% | Maxim Group | → $25 | Initiates Coverage On | → Buy |
| 12/21/2022 | 596.13% | Oppenheimer | $9 → $63 | Maintains | Outperform |
| 11/16/2022 | -39.23% | HC Wainwright & Co. | $6 → $5.5 | Maintains | Buy |
| 07/18/2022 | -22.65% | Oppenheimer | → $7 | Assumes | → Outperform |
| 05/18/2022 | -11.6% | Wells Fargo | $7 → $8 | Maintains | Overweight |
| 03/21/2022 | -22.65% | Aegis Capital | $9 → $7 | Maintains | Buy |
| 08/17/2021 | -0.55% | Aegis Capital | $10 → $9 | Maintains | Buy |
| 08/11/2021 | -28.18% | HC Wainwright & Co. | $7 → $6.5 | Maintains | Buy |
| 03/02/2021 | 10.5% | Aegis Capital | → $10 | Initiates Coverage On | → Buy |
| 09/23/2020 | -33.7% | BTIG | → $6 | Initiates Coverage On | → Buy |
| 08/05/2019 | -39.23% | HC Wainwright & Co. | → $5.5 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年09月21日 | 187.29% | HC Wainwright公司 | $23→$26 | 維護 | 買 |
| 2023年08月17日 | 297.79% | 奧本海默 | $63→$36 | 維護 | 跑贏大盤 |
| 2023年08月17日 | 154.14% | HC Wainwright公司 | →$23 | 重申 | 購買→購買 |
| 2023年05月31日 | 596.13% | 奧本海默 | →$63 | 重申 | 跑贏→跑贏大盤 |
| 2023年05月31日 | 154.14% | HC Wainwright公司 | →$23 | 重申 | 購買→購買 |
| 03/17/2023 | 154.14% | HC Wainwright公司 | →$23 | 重申 | →購買 |
| 01/04/2023 | 154.14% | HC Wainwright公司 | $5.5→$23 | 維護 | 買 |
| 2022年12月30日 | 176.24% | 考恩公司 | $6→$25 | 維護 | 跑贏大盤 |
| 2022年12月22日 | 176.24% | Maxim集團 | →$25 | 開始承保 | →購買 |
| 2022年12月21日 | 596.13% | 奧本海默 | $9→$63 | 維護 | 跑贏大盤 |
| 2022年11月16日 | -39.23% | HC Wainwright公司 | $6→$5.5 | 維護 | 買 |
| 07/18/2022 | -22.65% | 奧本海默 | →$7 | 假設 | →跑贏大盤 |
| 2022/05/18 | -11.6% | 富國銀行 | $7→$8 | 維護 | 超重 |
| 03/21/2022 | -22.65% | 宙斯盾資本 | $9→$7 | 維護 | 買 |
| 2021/08/17 | -0.55% | 宙斯盾資本 | $10→$9 | 維護 | 買 |
| 2021/08/11 | -28.18% | HC Wainwright公司 | $7→$6.5 | 維護 | 買 |
| 03/02/2021 | 10.5% | 宙斯盾資本 | →$10 | 開始承保 | →購買 |
| 09/23/2020 | -33.7% | BTIG | →$6 | 開始承保 | →購買 |
| 2019年08月05日 | -39.23% | HC Wainwright公司 | →$5.5 | 開始承保 | →購買 |
What is the target price for MediWound (MDWD)?
MediWound的目標價是多少？
The latest price target for MediWound (NASDAQ: MDWD) was reported by HC Wainwright & Co. on September 21, 2023. The analyst firm set a price target for $26.00 expecting MDWD to rise to within 12 months (a possible 187.29% upside). 11 analyst firms have reported ratings in the last year.
HC Wainwright&Co.於2023年9月21日報道了MediWound(納斯達克代碼：MDWD)的最新目標價。這家分析公司將目標價定為26美元，預計MDDD將在12個月內上漲至(可能上漲187.29%)。過去一年，有11家分析公司公佈了評級。
What is the most recent analyst rating for MediWound (MDWD)?
分析師對MediWound的最新評級是多少？
The latest analyst rating for MediWound (NASDAQ: MDWD) was provided by HC Wainwright & Co., and MediWound maintained their buy rating.
對MediWound(納斯達克代碼：MDWD)的最新分析師評級由HC Wainwright&Co.提供，MediWound維持買入評級。
When is the next analyst rating going to be posted or updated for MediWound (MDWD)?
MediWound(MDWD)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of MediWound, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for MediWound was filed on September 21, 2023 so you should expect the next rating to be made available sometime around September 21, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與MediWound的高管和客戶交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。MediWound的上一次評級是在2023年9月21日提交的，因此您應該預計下一次評級將在2024年9月21日左右提供。
Is the Analyst Rating MediWound (MDWD) correct?
分析師對MediWound的評級正確嗎？
While ratings are subjective and will change, the latest MediWound (MDWD) rating was a maintained with a price target of $23.00 to $26.00. The current price MediWound (MDWD) is trading at is $9.05, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的MediWound(MDWD)評級維持不變，目標價在23.00美元至26.00美元之間。MediWound目前的交易價格為9.05美元，超出了分析師的預測區間。